Vitamin D and mental health: what the evidence really says
By TherapyNearMe.com.au. General information only; not a substitute for personal medical advice. If you have concerning mood symptoms, speak with your GP or a registered psychologist. For urgent help, call 000; 24/7 support: Lifeline 13 11 14; Beyond Blue 1300 22 4636.
Key points at a glance
- Low vitamin D status is associated with higher rates of depressive symptoms in population studies, but supplementation does not reliably prevent depression in the general adult population (Okereke et al., 2020; Shaffer et al., 2014).
- In people with clinically significant depression or clear deficiency, some trials suggest modest benefit as an adjunct to therapy—but effects are heterogeneous and smaller than standard psychological or antidepressant treatments (Vellekkatt and Menon, 2019; Cuijpers et al., 2017).
- Evidence for anxiety, psychosis risk, and cognition is mixed; biological plausibility exists (vitamin D receptors and enzymes in brain tissue), but high‑quality causal trials are limited (Eyles et al., 2013; McGrath et al., 2010).
- In Australia, safe sun exposure must balance vitamin D needs with skin‑cancer risk. Routine population testing is not recommended; testing targets people at high risk of deficiency (Cancer Council Australia/ACD, 2023; RACGP, 2018).
What vitamin D is (and why the brain cares)
Vitamin D is a secosteroid hormone. After skin UV‑B exposure or intake from diet/supplements, it is hydroxylated in the liver to 25‑hydroxyvitamin D [25(OH)D], then in kidneys and other tissues (including brain and immune cells) to 1,25‑dihydroxyvitamin D, the active form. Vitamin D receptors (VDR) and 1‑alpha‑hydroxylase are expressed in neurons, glia and endothelial cells, suggesting roles in neurodevelopment, neuroimmune modulation, calcium signalling, and neurotransmission (Eyles et al., 2013).
Depression: what do the best studies show?
Observational links
Large cohorts show that lower 25(OH)D correlates with higher depressive symptoms scores and incident depression, particularly in older adults and those with chronic illness (Anglin et al., 2013). Correlation, however, is not causation: low vitamin D may be a marker of ill‑health, low outdoor activity, or poor diet.
Randomised trials and meta‑analyses
- Prevention in the general population: The VITAL‑DEP trial randomised 18,353 adults to vitamin D3 (2,000 IU/day) or placebo for ~5 years and found no reduction in risk of depression or clinically relevant depressive symptoms (Okereke et al., 2020).
- Treatment adjunct in depression: Meta‑analyses indicate small, variable improvements in depressive symptoms when vitamin D is added to usual care, with larger effects in people who are deficient at baseline or have clinically diagnosed depression (Vellekkatt and Menon, 2019; Shaffer et al., 2014). Study quality and dosing regimens vary substantially.
Bottom line: For most people, vitamin D alone is unlikely to prevent or treat depression. If you are deficient, correcting deficiency may support overall health and could augment standard treatments.
Anxiety, psychosis, and cognition: what we know
- Anxiety: Small RCTs in specific groups (e.g., perinatal women, medical conditions) suggest possible reductions in anxiety scores with supplementation, but results are inconsistent and under‑powered (Gur et al., 2014; Sarris et al., 2021).
- Psychosis and schizophrenia risk: Some case‑control and birth‑cohort studies link low neonatal 25(OH)D with higher schizophrenia risk (McGrath et al., 2010). Causality is unproven; preventive trials are lacking.
- Cognition: Observational studies associate low vitamin D with poorer cognitive performance in older adults, but trials correcting deficiency show mixed cognitive outcomes (Goodwill and Szoeke, 2017).
Seasonal mood and light: is vitamin D the lever?
Winter low mood in higher latitudes is more strongly improved by bright‑light therapy than by vitamin D supplements; evidence that vitamin D alone treats seasonal affective patterns is weak (Lam et al., 2016). Light affects circadian systems directly; vitamin D may be a parallel marker of reduced outdoor exposure rather than the primary driver.
Testing, targets and who is at risk (Australia)
- When to test: Not for everyone. Target testing to those at high risk: people with limited sun exposure (aged‑care, veiled clothing, shift or indoor workers), darker skin, malabsorption (bariatric surgery, inflammatory bowel disease), chronic kidney/liver disease, certain medications (anticonvulsants), and those with osteoporosis or recurrent falls (RACGP, 2018; DoHAC, 2024).
- Interpreting results: In Australian practice, 25(OH)D < 30 nmol/L is typically considered deficient; 50–60 nmol/L is commonly cited as a general target for bone health. There is no validated mental‑health‑specific threshold (RACGP, 2018).
Sunlight vs supplements in Australia: finding the balance
- Sun exposure: The Cancer Council and Australasian College of Dermatologists emphasise sun safety first. Short, frequent exposures outside peak UV times can maintain vitamin D for most people, varying by season and latitude. In high‑UV months, protect skin with shade, clothing, hats and SPF 50+ (Cancer Council Australia/ACD, 2023).
- Dietary sources: Oily fish (salmon, sardines), eggs, fortified milks and margarines contribute modestly (FSANZ, 2022). Diet alone rarely corrects significant deficiency.
- Supplementation: Common maintenance doses are 800–1,000 IU/day; higher doses may be used short‑term to correct deficiency under medical supervision. Avoid megadoses (e.g., 600,000 IU bolus) due to falls and fracture signals in some trials; stick to steady dosing unless directed by a clinician (Sanders et al., 2010). The tolerable upper intake level for adults is 4,000 IU/day (IOM, 2011).
Safety note: High vitamin D can cause hypercalcaemia (nausea, confusion, arrhythmias). Extra caution is needed in conditions like sarcoidosis or with thiazide diuretics—seek medical advice.
Where vitamin D fits in a whole‑person mental‑health plan
- Confirm the diagnosis and evidence‑based treatment: CBT/exposure for anxiety/OCD; behavioural activation and CBT for depression; trauma‑focused therapies where indicated; consider antidepressants where appropriate (NICE, 2011; 2018; Cuijpers et al., 2017).
- Check physical contributors: sleep, activity, iron/B12/thyroid where clinically indicated, and vitamin D if at risk of deficiency.
- Treat deficiency to general‑health targets while continuing first‑line mental‑health care.
- Prioritise daylight and movement: 20–30 minutes of outdoor activity most days supports circadian health and mood independently of vitamin D (White et al., 2024).
Common myths
- “Vitamin D cures depression.” Evidence does not support this. It can be a supporting element if you are deficient (Okereke et al., 2020; Shaffer et al., 2014).
- “More is better.” High‑dose boluses can be harmful; aim for steady, guideline‑consistent dosing (Sanders et al., 2010; IOM, 2011).
- “Testing everyone is necessary.” Not recommended; focus on risk‑based testing (RACGP, 2018).
Practical Q&A
Should I take vitamin D if I feel depressed?
Talk to your GP first. If you are at risk of deficiency, testing and replacement may help your overall health while you start first‑line treatments for depression.
Can sunlight alone fix low vitamin D?
Sometimes, depending on your location, season, skin type and habits. In winter or for people who avoid sun for medical/cultural reasons, supplements are often needed (Cancer Council Australia/ACD, 2023).
How long until levels improve?
With daily dosing (e.g., 1,000 IU), 25(OH)D typically rises over 8–12 weeks; your clinician may re‑check levels and adjust.
References
Anglin, R.E.S., Samaan, Z., Walter, S.D. and McDonald, S.D. (2013) ‘Vitamin D deficiency and depression in adults: systematic review and meta‑analysis’, British Journal of Psychiatry, 202(2), pp. 100–107.
Cancer Council Australia and Australasian College of Dermatologists (ACD) (2023) Position statement: Sun exposure and vitamin D. Sydney: Cancer Council Australia/ACD.
Cuijpers, P., Karyotaki, E., Reijnders, M., Purgato, M. and Barth, J. (2017) ‘Psychotherapies for depression: A meta‑analysis’, CNS Spectrums, 22(4), pp. 324–332.
DoHAC (Department of Health and Aged Care) (2024) ‘Vitamin D—consumer information’. Canberra: Australian Government. Available at: https://www.health.gov.au.
Eyles, D.W., Burne, T.H.J. and McGrath, J.J. (2013) ‘Vitamin D in fetal brain development: evidence, mechanisms and implications’, Trends in Neurosciences, 36(5), pp. 295–302.
FSANZ (Food Standards Australia New Zealand) (2022) ‘Nutrient tables and food composition: Vitamin D’. Canberra: FSANZ.
Goodwill, A.M. and Szoeke, C. (2017) ‘A systematic review and meta‑analysis of the effect of low vitamin D on cognition’, Journal of the American Geriatrics Society, 65(10), pp. 2161–2168.
IOM (Institute of Medicine) (2011) Dietary Reference Intakes for Calcium and Vitamin D. Washington, DC: National Academies Press.
Lam, R.W., Levitt, A.J., Levitan, R.D., Michalak, E.E., Cheung, A.H., Morehouse, R. and Tam, E.M. (2016) ‘Efficacy of bright light treatment for seasonal affective disorder’, Canadian Journal of Psychiatry, 61(1), pp. 14–23.
McGrath, J.J., Eyles, D.W., Pedersen, C.B., Anderson, C., Ko, P., Burne, T.H.J., Nørgaard‑Pedersen, B., Hougaard, D.M., Mortensen, P.B. and Nielssen, O. (2010) ‘Neonatal vitamin D status and risk of schizophrenia: a population‑based case‑control study’, Archives of General Psychiatry, 67(9), pp. 889–894.
NICE (National Institute for Health and Care Excellence) (2011) Generalised anxiety disorder and panic disorder in adults (CG113). London: NICE.
NICE (2018) Depression in adults: treatment and management (NG222). London: NICE.
Okereke, O.I., Reynor, K., Chang, S.C., Cook, N.R., Manson, J.E. and Buring, J.E. (2020) ‘Effect of long‑term vitamin D3 supplementation vs placebo on risk of depression or clinically relevant depressive symptoms’, JAMA, 324(5), pp. 471–480.
RACGP (Royal Australian College of General Practitioners) (2018) Guidelines for preventive activities in general practice — Vitamin D testing and deficiency. Melbourne: RACGP.
Sanders, K.M., Stuart, A.L., Williamson, E.J., Simpson, J.A., Kotowicz, M.A., Young, D. and Nicholson, G.C. (2010) ‘Annual high‑dose oral vitamin D and falls and fractures in older women’, JAMA, 303(18), pp. 1815–1822.
Sarris, J., et al. (2021) ‘Adjunctive nutraceuticals for anxiety disorders: systematic review and meta‑analysis’, World Journal of Biological Psychiatry, 22(7), pp. 493–507.
Shaffer, J.A., Edmondson, D., Wasson, L.T., Falzon, L., Homma, K., Ezeokoli, N., Li, P. and Davidson, K.W. (2014) ‘Vitamin D supplementation for depressive symptoms’, Psychosomatic Medicine, 76(3), pp. 190–196.
White, R.L., et al. (2024) ‘A systematic observation of moderate‑to‑vigorous physical activity in blue spaces’, Health Promotion International, 39(4), daae101.
Vellekkatt, F.I. and Menon, V. (2019) ‘Efficacy of vitamin D supplementation in major depression’, Journal of Postgraduate Medicine, 65(2), pp. 74–80.
How to cite this article
Therapy Near Me (2025) ‘Vitamin D and mental health: what the evidence really says’. Available at: https://TherapyNearMe.com.au (Accessed 9 December 2025).
